Intellia Therapeutics已正式启动其基因编辑疗法Lonvo-Z向美国食品药品监督管理局（FDA）的滚动生物制品许可申请（BLA）提交程序。这一关键步骤标志着该疗法向商业化迈出了重要一步。公司预计，若后续审查顺利，Lonvo-Z有望于2027年上半年在美国市场正式推出。
Intellia Therapeutics已正式启动其基因编辑疗法Lonvo-Z向美国食品药品监督管理局（FDA）的滚动生物制品许可申请（BLA）提交程序。这一关键步骤标志着该疗法向商业化迈出了重要一步。公司预计，若后续审查顺利，Lonvo-Z有望于2027年上半年在美国市场正式推出。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.